Octreotide and lanreotide are the two somatostatin analogs (SSA) currently available in
clinical practice. They have been approved first to control the clinical syndrome (mainly …

A growing body of literature reports on the combined use of peptide receptor radionuclide
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …

Background Pancreatic neuroendocrine tumors (pNETs) are rare cancers with outcomes
determined by multiple factors including grade, stage, and clinical presentation. In this study …

Purpose The purpose of this study was to develop a radiomics-signature using computed
tomography (CT) data for the preoperative prediction of grade of nonfunctional pancreatic …

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1
(G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) …

Objective: To determine the accuracy of preoperative imaging, including contrast-enhanced
computed tomography (CE-CT), endoscopic ultrasound (EUS), and 68 Gallium-DOTATOC …

Continuous progress in the diagnostics and treatment of neuroendocrine neoplasms
(NENs), the emerging results of new clinical trials, and the new guidelines issued by medical …

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor
radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine …

Gastrinomas are neuroendocrine neoplasms (NENs), that occur primarily in the duodenum
and pancreas, which ectopically secrete gastrin, resulting in the Zollinger-Ellison syndrome …

Methods: Retrospective review of prospectively collected clinicopathologic data of patients
who underwent pancreatectomy between 2000 and 2021 was collected from 4 high-volume …